Therapeutic Targets in Sepsis: Past, Present, and Future.

[1]  E Peterson,et al.  Early goal-directed therapy in the treatment of severe sepsis and septic shock. , 2018, The New England journal of medicine.

[2]  S. Lane,et al.  Circulating Histones Are Major Mediators of Cardiac Injury in Patients With Sepsis* , 2015, Critical care medicine.

[3]  Derek Bell,et al.  Trial of early, goal-directed resuscitation for septic shock. , 2015, The New England journal of medicine.

[4]  J. Jalife,et al.  Role of extracellular histones in the cardiomyopathy of sepsis , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Michael Bailey,et al.  Goal-directed resuscitation for patients with early septic shock. , 2014, The New England journal of medicine.

[6]  M. Bauer,et al.  Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation , 2014, Critical Care.

[7]  K. Tsumoto,et al.  Protective effect of the long pentraxin PTX3 against histone-mediated endothelial cell cytotoxicity in sepsis , 2014, Science Signaling.

[8]  Amber E Barnato,et al.  A randomized trial of protocol-based care for early septic shock. , 2014, The New England journal of medicine.

[9]  R. Bellomo,et al.  Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. , 2014, JAMA.

[10]  E. Ruokonen,et al.  A Multibiomarker-Based Outcome Risk Stratification Model for Adult Septic Shock* , 2014, Critical care medicine.

[11]  Renda Soylemez Wiener,et al.  Two Decades of Mortality Trends Among Patients With Severe Sepsis: A Comparative Meta-Analysis* , 2014, Critical care medicine.

[12]  Shein-Chung Chow,et al.  Adaptive clinical trial design. , 2014, Annual review of medicine.

[13]  D. Green,et al.  Anthracyclines induce DNA damage response-mediated protection against severe sepsis. , 2013, Immunity.

[14]  M. Fink.  Animal models of sepsis , 2013, Virulence.

[15]  J. Vincent,et al.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. , 2013, JAMA.

[16]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[17]  Jang-Gi Choi,et al.  Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model , 2012, Proceedings of the National Academy of Sciences.

[18]  E. Seeley,et al.  Inflection points in sepsis biology: from local defense to systemic organ injury. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[19]  R. Maharaj.  Vasopressors and the search for the optimal trial design. , 2011, Contemporary clinical trials.

[20]  Arthur S Slutsky,et al.  Broken Barriers: A New Take on Sepsis Pathogenesis , 2011, Science Translational Medicine.

[21]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[22]  Javier Llorca,et al.  Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study* , 2010, Critical care medicine.

[23]  A. Mantovani,et al.  Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality , 2010, Intensive Care Medicine.

[24]  Jun Xu,et al.  Extracellular histones are major mediators of death in sepsis , 2009, Nature Medicine.

[25]  Herbert L DuPont,et al.  The controversial and short-lived early use of rehydration therapy for cholera. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  A. Kalil,et al.  Why Are Clinicians Not Embracing the Results from Pivotal Clinical Trials in Severe Sepsis? A Bayesian Analysis , 2008, PloS one.

[27]  D. Lobo,et al.  The history of 0.9% saline. , 2008, Clinical nutrition.

[28]  Fernando A Bozza,et al.  Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis , 2007, Critical care.

[29]  D. Angus,et al.  Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis* , 2007, Critical care medicine.

[30]  K. Tracey,et al.  Role of HMGB1 in apoptosis-mediated sepsis lethality. , 2006, The Journal of experimental medicine.

[31]  K. Tracey,et al.  Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation , 2005, The Journal of experimental medicine.

[32]  K. Tracey,et al.  Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis , 2004, Nature Medicine.

[33]  Mitchell M. Levy,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[34]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[36]  T. Baskett.  William O'Shaughnessy, Thomas Latta and the origins of intravenous saline. , 2002, Resuscitation.

[37]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[38]  K. Reinhart,et al.  Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned , 2001, Critical care medicine.

[39]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[40]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[41]  Craig R. Smith,et al.  Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial , 1995 .

[42]  S. Nasraway,et al.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.

[43]  G. Koch,et al.  Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .

[44]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[45]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[46]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[47]  K. Tracey,et al.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.

[48]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[49]  B. Beutler,et al.  Cachectin and tumour necrosis factor as two sides of the same biological coin , 1986, Nature.

[50]  B. Beutler,et al.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.

[51]  B. Beutler,et al.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells , 1985, The Journal of experimental medicine.

[52]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[53]  W. Coley.  The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). , 1910, Proceedings of the Royal Society of Medicine.

[54]  B. Ligon,et al.  Penicillin: its discovery and early development. , 2004, Seminars in pediatric infectious diseases.

[55]  C. Starnes.  COLEYʼS TOXINS, TUMOR NECROSIS FACTOR, AND CANCER RESEARCH—A HISTORICAL PERSPECTIVE , 1993 .

[56]  A. Cerami,et al.  Lipoprotein Lipase Suppression in 3T3-L1 Cells by an Endotoxin-induced Mediator from Exudate Cells , 1984 .

[57]  C. Rouzer,et al.  Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. , 1980, Molecular and biochemical parasitology.